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ABSTRACT
LAKEN CHEYENNE HANCOCK: A Survey of the Presentation of Pharmacogenomic Testing
for Psychotropic Medications in Rural Areas
(Under the direction of Dr. John Young)
The purpose of this research is to assess the knowledge and opinions of the general public
in rural areas in regard to genetic testing and pharmacogenomics. 40 people from self-identified
rural areas participated in this study by completing an online Qualtrics questionnaire and an
in-person or online semi-structured qualitative interview. The Qualtrics questionnaire measured
demographic information, as well as depression, anxiety, stress, positive affect, and negative
affect using the Depression, Anxiety, and Stress Scale-21 (DASS-21) and the Positive and
Negative Affect Scale (PANAS) measures. The semi-structured qualitative interview included
questions pertaining to the decision support tool (DST) presented to participants, as well as
health-care preferences and likelihoods of pursuing specific strategies of intervention. Overall,
results indicated that the position of drugs within the DST visual framework had an effect on
respondents’ medication preferences. Qualitative data also suggested that these decisions were
made in the context of relatively little knowledge. In addition, participants indicated further
details such as side effects, medication ingredients, costs, addiction statistics, possible
medication interactions, dosages, and previous controlled clinical trial results as information they
would find helpful. Results from the study can be used to improve the implementation of
pharmacogenomic testing within rural medical settings.
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Introduction
What is Pharmacogenomics?
Pharmacogenomics studies the role that genetics plays within a person’s physical and
chemical response to pharmaceutical medications (Abul-Husn, Owusu Obeng, Sanderson,
Gottesman, & Scott, 2014; Abul-Husn. & Kenny, 2019). Through the role of pharmacogenomics
and genetic testing, personalized medicine has gained the potential to be utilized for widespread
medicinal treatments in the future. Genetic information can now be combined with the concept
of personalized medicine, which includes using a patient’s genetic testing results to see which
medications are more likely to be effective with minimal adverse effects for the individual
patient (Abul-Husn. & Kenny, 2019). In fact, many medications now include Food and Drug
Administration (FDA) pharmacogenomic labeling information (Schuck, Marek, Rogers, &
Pacanowski, 2019; Young, Bhattacharya, Ramachandran, Lee, & Bentley, 2021; Young, Jimenez,
Pruett, & Hancock, 2021). Drug metabolism, unique side effects, and non-responsiveness to
medication are among the many personalized reactions that can be identified and potentially
customized to ensure a more optimal treatment outcome for individual patients (Abul-Husn, &
Kenny, 2019; Young, et al. 2021). In addition, precision medicine provides the potential to
decrease healthcare costs as opposed to the current method of physicians prescribing medications
by base rate experiences, which are often based on personal anecdotal accounts.
Pharmacogenomic History
The idea of personalized medicine began in the late 90s and has since built a foundation
for better understanding treatment of diseases using genome sequencing, which has been aided
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by data collection through electronic health records (Abul-Husn & Kenny, 2019). Additionally,
genomic testing can reveal genetic proclivities to develop certain diseases, some of which are
identifiable by single gene markers (Abul-Husn & Kenny, 2019). With this innovation, carriers
of these disease variants can take additional steps to decrease their likelihood of developing
symptoms of the disease many years in advance, as well as make more informed decisions about
the propagation of those genes in future offspring. Despite rapid advances in this area of research
and technology development, genome sequencing remains a developing process with somewhat
imprecise application to only a few narrow dimensions of disease and disease variants.
The uptake of pharmacogenomics in clinical healthcare settings is relatively slow in
comparison to other medical breakthroughs and techniques, with most applications in use being
attributed to oncology due to comprehensible somatic mutations and distinct gene markers
(Lunshof & Gurwitz, 2012). Although there are several reasons for the seemingly stagnant
process, Amstutz and Carleton (2011) cited the imperative need for evidence-based clinical
practice guidelines for pharmacogenomics prior to widespread implementation in clinical
settings (Lunshof & Gurwitz, 2012; Nickola, Green, Harralson, & O’Brien, 2012). Likewise,
private sector drug companies have typically been disinterested due to lack of economic
incentives to administer or invest in pharmacogenomic testing as part of decision making within
controlled trials (Lunshof & Gurwitz, 2012). Lack of education for healthcare professionals also
promotes difficulty with objectivity and integration of the use of test results in clinical practice
settings (Lunshof & Gurwitz, 2012). Additionally, it is notable that post-graduate
pharmacogenomic training remains a pressing issue, as only 10% of a sample of 10,303 United
States physicians reported the perception that they were adequately knowledgeable about genetic
testing and pharmacogenetic implementation for patient treatment (Nickola et al., 2012).
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Likewise, a 2012 study of practicing nurses reported that only 30% of nurses had received
continuing education in genetics in the past two years (Thompson & Brooks, 2011). Pharmacists,
however, have shown substantially higher reports of positive attitudes towards
pharmacogenomics compared to physicians, and as a group are more willing to undergo
educational training related to pharmacogenomic principles (Nagy, Eirini Tsermpini, Siamoglou,
& Patrinos, 2020).
Although this openness to continuing education is useful and necessary for long-time
healthcare professionals, studies have also shown that health professional schools have not
generally updated genetic and genomic academic material to include the most recent
implementations of pharmacogenomics (Nickola et al., 2012). In a 2010 survey, for example,
76% of the 90 program respondents among United States and Canadian medical schools
indicated that their pharmacogenomic education was “poor” or “not adequate at all” (Nickola et
al., 2012). Likewise, a study of pharmaceutical schools found that while 89% of schools included
at least some pharmacogenomics education, less than half (47%) intended to increase their
amount of pharmacogenomics curriculum in the next three years (Nickola et al., 2012). Research
geared toward improving pharmacogenomic education suggests that the movement should be
prioritized and facilitated by pharmacists (as of 2020 over 50% of clinical sites offering
pharmacogenetic testing were pharmacist-led; Nagy et al., 2020; Nickola et al., 2012). Possible
methods of advancing continuing education in this domain include requiring
pharmacogenomic-relevant hours for licensure renewals, increasing undergraduate and health
professional school education, and incorporating all members of patient care teams in the
implementation of pharmacogenomics and precision medicine through a multidisciplinary
approach (Nagy et al., 2020; Nickola et al., 2012; Tsermpini et al., 2019).
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Rural Medicine
As of the 2017 Census, 60 million people, or 1 in 5 Americans lived in rural areas where
access to health-care has been measurably limited and among the primary issues cited as
problematic about rural life (Greenberg, Haney, Blake, Moser, & Hesse, 2017; Nasser, 2021).
Based on a survey of 250 health-care quality indicators, one in ten of these indicators have
worsened from 2000 to 2015 in rural areas, signifying the potential distal impacts of limited
access to adequate health-care services (Pourat et al., 2020). Additionally, rural residents are
more likely to lack a high-school education, rely on Medicaid coverage, fall in the United States
Federal low-income bracket, and have a poorer health status compared to urban areas (Pourat et
al., 2020). Further, Health and Resources Administration (HRSA) Health centers are the most
prominent or only source of medical service in many areas with the majority of patients being
older, white, female, obese, and uninsured compared to the general rural population, and with a
higher patient-to-physician ratio than notable in urban areas (Pourat et al., 2020). Health literacy
and access to health information technologies are also issues in rural communities, partially due
to two-thirds of rural counties being at or above the national poverty average (14.4%; Greenberg,
Haney, Blake, Moser, & Hesse, 2017). Specifically, most rural areas have limited internet access
and poor connection quality, which not only leave residents disadvantaged to the uses of
telehealth, but also health information technology (HIT) that helps monitor and self-regulate
one’s health (Greenberg, Haney, Blake, Moser, & Hesse, 2017).
The local context provides salient examples of these phenomena, given that Mississippi
was ranked 47th among states in 2021 by the United Health Foundation for the following four
health measures: outcome (number of health-related deaths, mental and behavioral health [e.g.,
excessive drinking, depression, and non-medical drug use], and physical health [with emphasis
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on chronic conditions]), behaviors (sleep health, sexual health, nutrition and exercise, and
tobacco use), clinical care (access to care, preventative services, and quality of services), and
community and environment (community safety, economic support, social structure, education,
air and water pollution, climate change, and transit; Connell, Wang, Crook, & Yadrick, 2019;
Explore health measures in Mississippi, 2021). In a study conducted in the Mississippi Delta,
participants cited structural barriers including transportation, lack of insurance, anticipated cost
of services, and insufficiency of healthcare availability or specialists as barriers to health-care
utilization (Connell et al., 2019). Likewise, other structural barriers include interpersonal factors
like lack of social support, fear of stigmas associated with disease and diagnosis, and fear of
health-care providers breaking confidentiality agreements (Connell et al., 2019).
In these rural communities, mental health is a major concern as substance abuse and
mental health difficulties are inordinately high. Compared to urban counties, suicide rates are
over 1.5 times higher (Summers-Gabr, 2020). Resources for mental health including
psychiatrists, psychologists, psychiatric nurse practitioners, and therapists are practically
non-existent in most rural areas as fewer than 10% provide services in rural settings (Hoeft,
Fortney, Patel, & Unützer, 2017). As a result, rural residents often only seek clinical mental
health consultation from their primary care providers and may be more likely to seek help in
non-clinical settings (e.g., friends, family, or spiritual guidance; Hoeft et al., 2017).
As a result of the COVID-19 pandemic, mental health issues increased, particularly
depression (potentially due to increased social isolation, fear of illness, sudden loss of family
members, job layoffs, and dramatic change in everyday lifestyle; Diamond & Byrd, 2020;
Matias, Dominski, & Marks, 2020). In order to better serve rural areas, telehealth medicine has
become increasingly more popular in rural settings (Hoeft et al., 2017). With regard to the
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current study, it is potentially relevant to note that Mississippi began a telegenetics clinic in an
effort to reach rural populations, which Medicaid and all private insurers operating within the
state are legally required to cover (Boothe & Kaplan, 2017). This program is not widely known,
however, and can only serve a small number of patients due to limited availability (Boothe &
Kaplan, 2017). Due to socioeconomic statuses, lack of technological education, and isolated
areas without access to broadband internet, telehealth opportunities are not ideal or accessible for
all residents of rural areas. As a result, many mental health conditions remain undiagnosed or
untreated in rural areas and eventually lead to hospitalizations in many cases, especially among
children (Bettenhausen et al., 2021). In addition to the lack of proper mental healthcare access,
rural physicians often feel unequipped for adequate treatment.
In general, this lack of resources leads to primary care providers being the go-to source
for all rural residents’ healthcare needs, including psychiatric (Avery, Dwan, Sowden, & Duncan,
2020). The interventions employed in this context are overwhelmingly biomedical, meaning that
they have some propensity to be affected by genetic structure (consistent with
pharmacogenomics research). This could be beneficial in some cases, although research suggests
that current consultations on genetic testing often leave people feeling like they have received
inadequate information due to limited healthcare literacy and lack of further explanations being
offered about complex genetic concepts (Barton, Wingerson, Barzilay, & Tabor, 2018). Yanes et
al., for example, cited common reactions of anxiety, fear, frustration, isolation, and uncertainty
following the receival of genetic testing results (Yanes, Humphreys, McInerney-Leo, &
Biesecker, 2016). Extensive consultation training should be implemented in clinical practice to
reduce these fears, as many patients are currently seeking the majority of support and
understanding from online platforms and media sources, which commonly display
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misinformation and biases (Barton et al., 2018). Unfortunately, research in this domain has been
limited and the most optimal methods of communication about pharmacogenomic results are as
yet unknown.
Pharmacogenomics for Mental Health in Rural Areas
Pharmacogenomic testing has been studied with various psychotropic medications, where
these techniques have been shown to be beneficial to treatment outcome (particularly with
antidepressants; Schuck et al., 2019). Because most people in rural areas with depression or
anxiety do not have access to specialty mental health resources, they disproportionately see their
primary care physicians when they seek help for emotional symptoms. In this non-specialized
environment, pharmacogenomic testing could provide numerous advantages to guide treatment.
For example, pharmacogenomic testing for anxiety and depression can remove the usual “trial
and error” work in seeking the appropriate prescription for a given individual (Schuck et al.,
2019). As an example, for Major Depressive Disorder (MDD), 30 to 50% of patients did not
respond to their first prescribed medication treatment when treated without the benefit of not
using pharmacogenomic testing, a rate that was significantly diminished in a randomized sample
of people who received testing at treatment onset (Yoshida, Müller, & Kennedy, 2019). Based on
a previous study between treatment of patients with depression guided by pharmacogenomic
testing and unguided (standard treatment), remission rates of those with pharmacogenomic
testing were also significantly higher (OR 1.7; Schuck et al., 2019; Yoshida, Müller, & Kennedy,
2019). Thus, there is some randomized evidence to suggest that pharmacogenomic testing could
improve treatment outcomes in general settings (such as those typically encountered in rural
settings) among people experiencing mental health concerns.

7

Clinical Implementation
Given the potential benefits and rapidly increasing applied use of pharmacogenomic tests,
additional research on their implementation, utilization, and refinement is imperative. In
particular, understanding patient responses to the in-clinic presentation and administration of
genetic testing and pharmacogenomic results is necessary to understand the interpretation and
applied use of these tests. Without demonstrable evidence of clinician and/or patient
understanding of the outcomes of these tests, which are often very difficult to interpret, their use
may confound treatment decision-making rather than improve it. In general, there is also
evidence that patients do not easily tolerate changes in typical treatment procedures (which are
often defined by their own stereotypes of physician-patient interaction). For example, Abul-Husn
and colleagues (2014) proposed three questions to consider when discussing how to establish an
acceptable reputation for a new-to-patient treatment plan that involves genetic data (Abul-Husn
et al., 2014). The questions are as follows: “Are patients open to and interested in receiving
personalized genetic testing information? What is the effect of personalized genetic testing
information on psychological well-being? Does personalized genetic testing information
motivate patients to improve their health-related behaviors?” (Abul-Husn et al., 2014) Through
their research of a group of compiled studies, the team concluded that patients have an overall
positive attitude towards undergoing pharmacogenomic testing, and their willingness increased
with the severity of the diseases being tested (Abul-Husn et al., 2014). However, the authors also
indicated that not many studies had been conducted on the topic, and clarity of the patient’s role
in the process was limited (Abul-Husn et al., 2014).
Cost efficiency also remains uncertain with regards to the value of conducting
pharmacogenomic testing on each patient prior to beginning treatment (Schuck et al., 2019).
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Many insurance companies like Medicare classify these drug-gene interaction tests as
preliminary and provide little or no reimbursement in their healthcare plans, making the
feasibility of accessing tests more limited when considering all potential patients (Keeling et al.,
2019). These conditions could be changing, though, as knowledge of these techniques becomes
more widespread. In a 2019 Keeling et al. study, for example, insurance payers stated that they
valued the information published by the Clinical Pharmacogenetic Implementation Consortium
(CPIC) for pharmacogenomic information, which could be informative in encouraging insurance
companies to adopt preemptive pharmacogenetic testing into coverage policies (Keeling et al.,
2019). This consortium regularly reviews and issues policy statements concerning the
effectiveness of various pharmacogenomic tests for specific classes of medications, potentially
making it a valuable resource in future dissemination of these techniques.
Current Pharmacogenomic Presentation
Lack of federal health guidelines for pharmacogenomic testing is cited as a common
barrier for clinical implementation of pharmacogenomic decision making. As of 2018, 19
guidelines over 44 drug-gene interactions had been published by the CPIC (Beckett, Kisor,
Smith, & Vonada, 2018; Relling & Klein, 2011). These guidelines aim to assist physicians and
other healthcare providers who are not formally trained in pharmacogenomics. In their literary
analysis of guidelines, Beckett et al. (2018) found that only 3 of 49 peer-reviewed articles
addressed therapeutic guidelines for psychiatry. While these guidelines use evidence-based
approaches for instruction, they do not cover all possibilities, and ambiguity is a result of
experience and a care provider’s own individualized approaches (most of which do not entail a
strong knowledge of genetics or genetic testing; Beckett et al., 2018).
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Although there is not a specific clinical approach found to be the most appropriate for
timing of pharmacogenomic testing and delivery methods of results to patients, there are multiple
adequate approaches that can be modeled. While testing can be executed preemptively or when
the need arises, many clinicians propose an interdisciplinary testing approach that could be
standardized (Zierhut et al., 2017). In order to keep patients informed on the process, some
healthcare advisors suggest that a pretest and posttest counseling session should be administered
for patients, while others in clinical settings deem this unnecessary in gauging patient clarity and
understanding (Zierhut et al., 2017).
Given the complexity of tests and lack of clinical standards, there are several beneficial
decision support tools (DST) available to aid clinicians seeking to utilize pharmacogenomic tests
in practice. One of the most prevalent is from Genesight, which provides a visual interpretation
tool to assist health-care providers who lack confident education and experience in
pharmacogenomics (Pyzocha, 2021). The actual GeneSight genetic test currently analyzes 57
neuropsychiatric medications and 12 genes with a measurable 100% accuracy rate at a molecular
genetic level (Pyzocha, 2021). As a visual aid for patients and providers, the test categorizes
risks of medications by a green, yellow, and red color code. The green code indicates a use as
directed approach (low risk), yellow signifies a moderate gene-drug interaction (moderate risk),
and red cautions significant gene-drug interactions (high risk; Pyzocha, 2021). In addition to the
yellow and red color codings, these two sections are also broken down into subsections
indicating further cautions or instructions for the healthcare provider, including high or low
dosage warnings, adverse side effect risks, and conflicting dose adjustments due to the patient’s
metabolism (Pyzocha, 2021). While the GeneSight test can be administered at home, only
physicians registered through the GeneSight database are able to order the test for a patient,
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unlike many commercial genetic testing kits (Pyzocha, 2021). However, misconception of the
prediction of treatment effectiveness may be skewed in patient understanding, so test result
analysis should be interpreted and ultimately used as a resource for decision-making rather than
the treatment standard (Pyzocha, 2021). Although it is not currently FDA approved, Medicare
fully covers the $1,569 cost of the test, and other private providers typically cover $1,239 or
more of the cost of testing (Pyzocha, 2021).
Purpose of Current Study
On account of the literature reviewed, this study has been designed to evaluate the
opinions of the general public in rural areas in regard to genetic testing and pharmacogenomics.
A previous study conducted by surveying students at the University of Mississippi collected data
on the presentation of genetic testing; however, the surveyed sample was not representative of a
primary care setting because the majority of respondents were recruited from psychology classes
and were more knowledgeable than the general public on the topic of pharmacogenomics (Young
et al., 2021). Thus, this study will analyze rural residents’ opinions on genetic testing and using
their personalized results to make healthcare decisions, as well as their understanding of
pharmacogenomic testing results. Likewise, this study will help future researchers determine
what should be discussed during a consultation regarding genetic testing, and potentially develop
insights about how pharmacogenomic test results could ideally be presented in order to receive a
positive response in rural communities.

11

Methods
Participants
For this study, residents of rural areas were recruited. A total of 40 people participated, 27
of whom were male (67.5%) and 13 of whom were female (32.5%). Participant age ranged from
18 to 88 years of age, with the average being 38.80 (SD = 21.62). The modal participant was 21
years old (n = 8; 20%) and Caucasian (n = 38; 95%). Participants were recruited by word of
mouth in and around Waynesboro, Mississippi (the author’s hometown), although some
participants were from rural areas of Tennessee, Georgia, and Alabama (with ties to Mississippi
that facilitated their recruitment to this study). Participants received no compensation or
incentives for participation. Interviews for the study were conducted in person and online
through Zoom video conferencing, which was left to the discretion of the participant due to the
COVID-19 pandemic. Living in a self-reported rural hometown was the only limiting criterion
for participation in this study. Education level of participants ranged from middle school or less
(n = 2; 5%) to graduate degrees (n = 2; 5%). The most common report of education level was
“Some College” (n = 16; 40%). The education level of each participant’s parents was also
reported, and the levels ranged from middle school (n = 8; 10%) or less to doctorate degrees (n =
1; 1.25%). The modal level of education for participants’ parents was high school (n = 38;
47.5%). Additionally, 17 participants (42.5%) reported that they were parents (step-parent, foster
parent, or any other type of guardian was included in this description). Prior to the recruitment of
participants, Institutional Review Board approval was obtained for the study.
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Measures
Through the course of this study, each participant’s responses were measured through
three different analyses. A Qualtrics survey was used to collect self-report data and participant’s
background information. This entailed administration of the two measures outlined below, which
was followed by a more in-depth interview about individuals’ perceptions of pharmacogenomic
testing using an applied analogue method previously implemented in local studies conducted in
the same lab.
Depression, Anxiety, and Stress Scales, 21-Item Version (DASS-21). The DASS-21 is
the shortened version of the original Depression, Anxiety, and Stress Scales, 42-Item Version
(DASS-42) and is designed to measure anxiety, depression, and stress over a period of two weeks
(Young et al., 2021; Osman et al., 2012). The 21 question survey is divided into three sub-scales
to indicate the presence of anxiety and depressive disorders through a four-point Likert-type
scale (Young et al., 2021; Osman et al., 2012). Response choices are designed to rate how much
a participant agrees or disagrees with a statement or how the participant feels that the description
applies to them (Sullivan & Artino, 2013). Previous research has indicated that the instrument
has strong psychometric properties confirmed by both exploratory and confirmatory factor
analysis. Reliability levels confirmed by internal consistencies were relatively high (depression
0.91; anxiety 0.81; stress 0.9; Lovibond & Lovibond, 1995). The DASS-21 also has known
norms (Lovibond & Lovibond, 1995). The instrument appears in Appendix 1.
Positive and Negative Affect Scales (PANAS). The second measurement used through
the Qualtrics survey is The Positive and Negative Affect Scales (PANAS). The PANAS scale
used in this study has the ability to measure both positive and negative affect over the past week
using a five-point Likert-type scale (Young et al., 2021). For the specific questionnaire,
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participants indicated their opinions through “Strongly Disagree, Mildly Disagree, Neither Agree
nor Disagree, Mildly Agree, Strongly Agree” options to the questions shown in Appendix 2.
Research conducted testing the reliability of the PANAS scale found the tool to have high
internal consistency defined by alpha coefficients for positive and negative affect (PA 0.86; NA
0.87; correlation 0.09; Watson, Clark, & Tellegen, 1988). There are also established norms for
the PANAS tool (Watson, Clark, & Tellegen, 1988).
Semi-structured qualitative interview. The final measure, which was administered by
the researcher, was a semi-structured qualitative interview shown in Appendix 3. The interview
questions used in this study were an adaptation of the survey questionnaire utilized in a study by
Young et al. (2021), which is currently under review for publication (Young et al., 2021).
Consistent with the desire to learn more about these issues in rural populations, questions
regarding rural health-care were added to the questionnaire. The interview-style questionnaire
was designed to assess confusion, concerns, and approval indications through broad likelihood,
opinionated, or rank style questions. It was administered following a standardized presentation of
genetic results, which were fabricated but done using a template based on the commercially
available GeneSight tool, which has been used in numerous studies. The DST used was
color-coded green, yellow, and red (mirroring GeneSight’s risk-color association). It displayed
both brand and generic names for each medication but did not include any other information.
Additionally, fluoxetine/Prozac was used as the target of manipulation due to the identifiability
of the medication.
Procedure
Participants first responded to the Qualtrics questionnaire containing the demographic,
DASS-21, and PANAS parameters. The questionnaire was completed in the presence of the
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researcher each time either in-person or through the online program Zoom. By completing the
Qualtrics survey, participants’ consent to participate was indicated. Participants were notified
that they were not required to answer any questions that made them uncomfortable and could opt
out of the study at any time. Following the Qualtrics questionnaire, participants were randomly
assigned to groups (one control group and three experimental groups). The randomized sample
assignments are displayed in Figure 1. To begin the semi-structured qualitative interview,
participants were read a prompt and given a sample DST that coordinated with their assigned
group. Each DST dashboard maintained the same medications, but fluoxetine’s placement in the
DST differed between green, yellow, and red categories. A sample dashboard is displayed in
Appendix 4.
Figure 1. Participant assignments

The prompt for the semi-structured qualitative interview remained the same across each
experimental cohort, but the control group was not told that fluoxetine was the most
recommended for the participant’s age group. The prompt is similar to the statement used in a
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study by Young et al.; however, depression in the prompt has been replaced with anxiety for this
study (Young et al., 2021). The prompt for the experimental groups is shown below:
I want you to pretend that you have a lot of anxiety and went to see a psychiatrist, who
suggested that you should undergo genetic testing before starting any medication. As the
psychiatrist explained, this testing looks at your genetic code and predicts which
medications are likely to work best and worst. I’m going to give you a feedback form that
shows the results of this genetic testing. It’s pretty similar to how some of these forms
actually look, and all the medications listed are real. Even though the results are fake,
think of them as though they were the real results of your own genetic testing. Also, be
aware that the most commonly prescribed medication for anxiety for people in your age
group is fluoxetine/Prozac. Take a minute to look over the form and learn what you can,
and then I’ll ask you a few questions about your reactions.

After the prompt was read to each participant, they were asked to select a medication from the
dashboard that they would choose to take based on their interpretation of the DST and the
prompt (despite whether or not using medication aligns with their personal dispositions). After
choosing a medication, participants were asked a series of questions that were constant across
each group. Most of these questions were structured to encourage dialogue and any additional
information the participants wanted to add. However, two questions were polar interrogatives
and one question was a rank-order question to better quantify data on health resource availability
and preference for mental health treatment.
Data Analysis
A Chi-square test of independence was conducted between the “green”, “yellow”, and
“red groups”, and once again in reference to the control and “yellow” groups. The Chi-square
test of independence was conducted with the assumption that all categorical variables were
mutually exclusive and were equal in chosen probability. Demographic variables and qualitative
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information were quantified and their frequencies were calculated. The “Results” section
highlights all outliers of the analysis.
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Results
A summation of the frequency of each drug category (“green”, “yellow”, and “red”)
chosen can be seen below in Table 1. The Chi-Square comparisons across each drug category
indicate that there is a significant difference in the frequency of which drugs were selected within
each category (X2 (4) = 12789 p < 0.001). In each group, the “green” medication category was
chosen the majority of the time; 87.50% (n = 7) chose the “green” category in the “green”
participant group (low risk), 60% (n = 6) chose the “green” category for the “yellow” participant
group (moderate risk), 63.64% (n = 7) chose the “green” category for the “red” participant group
(high risk), and 72.73% chose the “green” category for the control group. Fluoxetine, also listed
as the brand-name medication on the DST, was most commonly chosen as the medication
preference in the “green” participant group (87.50%; n = 7), which listed fluoxetine in the
“green” low-risk category.
Table 1. Medication categories chosen by each group
Participant Group

Medication Category Chosen
Green

Yellow

Red

Greena

7

0

1

Yellowb

6

3

1

Redc

7

2

2

Controld
a

8
b

3
c

0
d

chose fluoxetine (87.5%); chose fluoxetine (30%); chose fluoxetine (9.09%); chose fluoxetine (18.19%)
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The one participant in the “green” group explained that a “red” category medication was chosen
because the participant was familiar with the drug chosen. Additionally, the participant
interpreted the “red” category label (“use with increased caution and with more frequent
monitoring”) as the participant receiving frequent monitoring by physicians, which the
participant expressed a desire to have. Most of the “yellow” and “red” participants chose
medications that were not labeled in the “green” category due to fluoxetine’s placement in the
DST. The three participants who chose medications in the “yellow” categories within the control
group (who were not notified of any prescription base rates) each had varying answers to explain
their choice. One participant chose the “yellow” category description (“use with caution”)
because they always used caution with medications and interpreted the “yellow” category to be
the best fit for them. Another participant explained they perceived the riskiest medications to be
the most effective, however, they would not be willing to try the most risk-inclined (“red”)
group, and they perceived the “green” group to not be effective enough. This reasoning was also
cited one other time throughout the study for a separate participant category. The final participant
to choose a “yellow” category medication made their decision based on familiarity with the
medications. When comparing the “yellow” category and the control group, no differences were
shown in the frequency of medication selection (X2 (2) = 1.24; p = 0.54). 50% of participants (n
= 20) stated that without the color coding indicators in the DST, they would have chosen a
different medication, mostly at random. Those who would choose the same medication (50%; n
= 20) most commonly stated that they chose the medication that they were the most familiar
with.
The mean comparisons (ANOVAs) of the DASS-21 (depression, anxiety, and stress) and
PANAS (positive and negative affect) scores are displayed in Table 2. Overall, all participants
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were within normal limits for positive affect, however, 13 participants (32.5%) were at least one
standard deviation above the mean for negative affect. Only a few participant scores were
elevated for symptoms of anxiety (1 severe and 1 moderate), depression (1 moderate), or stress
(1 moderate). Because participant scores remained in normal limits for the majority and did not
differ across groups, these measures were unlikely to affect participants’ responses to the survey
questions.
Table 2. PANAS and DASS-21 Self Report Scores
Measure

Mean (σ)

Depression

3.18 (3.98)

Anxiety

2.63 (3.61)

Stress

5.53 (4.60)

Positive Affect

32.05 (6.64)

Negative Affect

12.13 (9.11)

For the quantitative data in the semi-structured qualitative interview, the average
likelihood of taking medication (61.08%) to treat clinically diagnosed anxiety was higher than
the likelihood of attending therapy (53.38%). Participants most commonly referenced fear of
addiction and negative effects as reasons for their disinterest in medication, while stigma and fear
of judgment were reported reasons for the concerns with therapy. In addition, the average
likelihood of undergoing genetic testing was 55.88%; however, 48 participants (96%) indicated
that they would be more likely to undergo genetic testing if the tests were to predict serious
illnesses or traits that they might pass on to their children. The two participants who said their
likelihood would not be changed indicated that there was a 0% likelihood of undergoing genetic
testing under any circumstances. These likelihoods are referenced in Table 3.

20

Table 3. Quantitative summary of likelihoods from the semi-structured qualitative interview
Circumstance

Percentage of Likelihood

Medication

61.08%

Therapy

53.38%

Genetic Testing

55.88%

Despite the lower likelihood score of attending therapy, 18 participants (45%) indicated
that they believed therapy to be superior rather than medication (question 4 on the interview
questionnaire), while only 11 participants (27.5%) viewed medication as superior and 11
participants (27.5%) felt that neither were superior. In addition, 21 (52.5%) participants stated
that they would not take medication in conjunction with therapy, 12 (30%) participants expressed
no concern and were willing to take medication while attending therapy, and 7 participants
(17.5%) stated that if they needed (as indicated by their physician) to take medication at the same
time, they would have no objections to doing so.
Information gathered in response to questions 10, 11, 12, and 13 surveyed health-care
preferences and accessibility. Of the participants surveyed, 80% (n = 32) reported that they travel
to a different city for access to health-care. In addition, 20% of participants (n = 8) were able to
name a mental health resource in their hometown other than their primary care physician. These
resources include the following: mental health facilities (n = 3), counselors (n = 3), health
departments (n = 2), and psychiatrists (n = 1). When given the choice between consulting a
psychiatrist or primary care physician for the participant’s first visit regarding mental health,
80% of participants (n = 32) said they would visit their primary care physician first. The rank
order question surveyed where participants would choose to go for help if they had severe
anxiety. The full frequency measure can be viewed below in Table 4.
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Table 4. Quantitative data for the rank-order interview question (Question #12)
1st Choice

2nd Choice

3rd Choice

Psychiatrist

0

Psychiatrist

4

Psychiatrist

5

Psychologist

1

Psychologist

0

Psychologist

5

Therapist

3

Therapist

4

Therapist

8

Primary Care
Physician

10

Primary Care
Physician

15

Primary Care
Physician

11

Friends &
Family

11

Friends &
Family

13

Friends &
Family

5

Online
Resources

15

Online
Resources

4

Online
Resources

6

4th Choice

5th Choice

6th Choice

Psychiatrist

8

Psychiatrist

12

Psychiatrist

11

Psychologist

11

Psychologist

16

Psychologist

7

Therapist

17

Therapist

4

Therapist

4

Primary Care
Physician

2

Primary Care
Physician

2

Primary Care
Physician

0

Friends &
Family

1

Friends &
Family

3

Friends &
Family

7

Online
Resources

1

Online
Resources

3

Online
Resources
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For the qualitative interview, participants commonly expressed the desire to research the
medications online, talk to others who have taken the medications, or consult their primary care
physician before choosing a medication from the DST. Participants commonly noted that beyond
the name of the medications, they would also like to know side effects, medication costs,
addiction statistics, dosages, interactions with other medications, and if the medication is a
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selective serotonin reuptake inhibitor (SSRI). Lifestyle change, removing stressors, breathing
and relaxation techniques, healthy dieting, herbal medicine, exercise, and religion were among
the most common ways participants would try to address anxiety aside from medication and
therapy. When participants were asked how they may respond if they received a DST with only
medications in the “red” category, most indicated they would experience frustration, sadness, or
hopelessness, but would be more willing to seek other treatments like therapy. In addition, the
majority of participants stated that they would like a second opinion fromanother healthcare
provider. Only 11 participants (27.5%) expressed a specific concern regarding genetic testing;
these included: lack of knowledge, possibility of discovering deadly disease, legal privacy and
ownership of test results, and pharmacogenomic testing reliability.
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Discussion
The results of this study show that the DST organization of psychotropic medications had
a significant influence on the decisions of the participants. This is particularly true when the base
rates of fluoxetine aligned with the “green” category of the DST, as 87.5% of participants chose
a medication in the “green” category, which is a higher percentage than any other category or
participant group. Several participants misinterpreted the color-coding of the DST, and while this
could be a representation of limited health literacy in rural areas, this may also be attributed to
the method of presentation of the DST, which was designed to be implemented in a clinical
setting with the assistance of a (at least somewhat) knowledgeable provider. Despite the success
of the DST coding, many still chose their medications based on base rate, which could imply
participant’s discomfort in making their own health-care decisions or previous familiarity with
the medication (fluoxetine was the most well-known medication overall). However, 50% of
participants depended solely on the DST as they indicated that without the color-coding, they
would have picked a medication completely at random. So while confidence in using
pharmacogenomic indicators to make decisions needs improvement through education for
patients and training for health-care providers, the implementation of using a DST for decision
making is still accepted by a large number of participants (particularly considering the
disadvantaged factors of rural areas and relative lack of familiarity with these techniques).
Willingness to undergo genetic testing also yielded a low percentage of participants
overall (55. 88%). While those who expressed apprehensions toward genetic testing noted
concerns of privacy, possibility of fatal genetic diseases, and reliability, 29 participants reported
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that they did not have any concerns, and while 12 participants indicated that they were 100%
willing to undergo genetic testing, 17 participants remained who were 100% unwilling to
undergo genetic testing but referenced no specific concerns. Not referencing specific concerns
can be indications of negative stigma surrounding genetic testing due to misconceptions,
although this is speculative and the reasons for their adamant position against genetic testing
were not entirely clear.
Rural area education disparities were also consistent with previous research, with the
majority of participants having the highest degree of a high school diploma and some college
courses. The highest level of education of the participants’ parents was most commonly
identified as high school (with many not receiving high school diplomas). While participants
most commonly possessed a higher level of education than their parents, it is important to note
parental education levels because if parents did not receive a high education level or have high
levels of health literacy, then participants would be likely to lack additional relevant learning
resources during their early development (e.g., home learning environment), which could affect
their orientation to the questions posed in this study.
Throughout the semi-structured qualitative interview survey, an extreme reference to
primary care physicians was made, which can be explained by the lack of health resources in
rural areas that lead primary care physicians to take on many roles. Reliance on primary care was
demonstrated for many to be attributable to a lack of health-care resources, which was confirmed
by the large percentage (80%) of participants traveling to different cities for any health-care
access. In addition, in response to the rank-order question, no participants chose to see a
psychiatrist as their first choice, and only one chose to seek a psychologist. Generic “online
resources” were the most common selection for participants’ first choice, which is not ideal
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considering the amount of misguided health information that is accessible on the Internet. While
this was the most preferred resource, many also cited the lack of reliability of online information,
and as a result, 11 participants chose online resources as their last resource choice. Participants
most often chose to seek guidance from therapists, psychiatrists, and psychologists as their last
options (4th, 5th, and 6th choices). Reasons for this include limited access (only one participant
cited the access of a psychiatrist in their hometown) and preference (80% of participants stated
they would rather seek assistance from the primary care physician than a psychiatrist for their
first consultation regarding mental health). In addition, those who were able to name therapy
resources in their hometown often said they would refrain from visiting them due to fear of a
privacy breach. This concern of privacy remains a large interpersonal factor in seeking medical
services in rural areas as the fear was also cited in a study conducted in the Mississippi Delta
(Connell et al., 2019).
After reviewing participants’ concerns, confusions, and recommendations, beneficial
information for in-clinic implementation of pharmacogenomic testing and decision-making could
be discerned. Overall, more explanations of the physical testing process are likely needed
alongside informing the patient of confidentiality policies, given respondents’ apprehension
about the method of testing. Additionally, pre- and post-testing consultation proposed by
previous research would be beneficial to offer in order to alleviate fears of genetic testing and
emotionally processing the results (Zierhut et al., 2017). Finally, participants indicated that in
addition to the DST, information provided to patients should include side effects, medication
ingredients, dosages, possible medication interactions, addiction statistics, costs, and previous
controlled clinical trial results.
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Limitations
Due to the demographics of the geographic region participants were recruited from, the
study lacked diversity in race and ethnicity. In addition, socioeconomic statuses were not
measured. Differing socioeconomic statuses may affect access to healthcare, previous education
levels, health literacy, and opinions on health care providers, which could substantially influence
results. The small sample size of this study and localized data also limited the generalizability to
outside regions and states.
Future research
Significance for future research includes broadening the scope of participant recruitment
and surveying a larger number of females to determine the influence that gender may have on the
perception of genetic testing. In addition, this study chose to use the hypothetical diagnosis of
anxiety in order to obtain the most transparent results. However, substituting the word
“depression” in the script for “anxiety” may also be implemented to test the effect of the more
negative connotations of depression in a rural area. Future studies could also manipulate the
setup of the experiment, including using a less commonly known drug for the base rate in the
prompts.
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Personal Reflection
Upon beginning this study, I possessed a strong desire to become a physician in a rural
area, due to witnessing the effects of health-care scarcities in my own rural community. I chose
to survey my rural community after witnessing multiple friends and family members struggle
with mental health diagnoses. As a result of conducting this study and analyzing the data, I have
acquired an increased motivation to help educate my community (and hopefully beyond) on the
positive benefits of pharmacogenomic testing as well as improve health literacy. In addition, I
endeavor to one day become a rural physician who remembers the need for continued education
and collaboration with mental health experts in order to give patients the best care possible.
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APPENDIX 1
Depression, Anxiety, and Stress Scales, 21-Item Version (DASS-21)
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APPENDIX 2
Positive and Negative Affect Scale-PANAS
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APPENDIX 3
Semi-Structured Qualitative Interview Questionnaire
1) What information did you use to make your decision about the specific drug you’d prefer?
Tell me about your thought process and reasoning. If you had all the time you wanted, what
additional steps (if any) would you have taken before deciding?
2) How much sense were you able to make of the feedback form? What could have made it
easier for you to understand? What other information would you like to have included beyond
the list of medications?
3) From 0 – 100%, how likely would you be to seek medication if you were diagnosed with
clinical anxiety? What else might you do to address your symptoms? Would you have any
difficulty with or objections to staying on anti-anxiety medication for the rest of your life? Why
or why not?
4) From 0 – 100%, how likely would you be to seek therapy if you were diagnosed with clinical
anxiety? What factors would influence your decision to do so (or not do so)? Would you want to
take medication at the same time? Between medication and therapy, do you view one of these
approaches as superior? Why or why not?
5) Would your decision have been different if you didn’t have the results of genetic testing but
were presented with the same list of drugs? How so? What information would you use to make
your decision in that case?
6) If this were a realistic situation, what else would you want to know? What kinds of emotional
reactions would you likely have? What kinds of additional tests or interactions with healthcare
providers would you want?
7) From 0 – 100%, how willing would you be to engage in genetic testing if your doctor
recommended it? Does your opinion change in terms of what’s being tested (for example,
depression medication vs. likelihood of developing a terminal disease vs. learning about the
characteristics you might pass on to your children)? What concerns do you have with the process
of genetic testing in general? More specifically and hypothetically, what concerns would you
have with using your own results in making important healthcare decisions? If there’s anything
that “feels” weird to you about this kind of testing I’d like to hear about that too.
8) Imagine the same situation we just talked through, but every single medication on your
feedback form is in the “red” box (meaning they’re all predicted to not work very well for you
due to your genetic structure). How would that information affect you? In particular, what kinds
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of emotional reactions might you have? What would you do to address your symptoms as a result
of this information?
9) What else comes to mind that would help us understand people’s reactions to this type of
information and/or use of it in making healthcare decisions?
10) To what extent can people in your hometown get access to mental health services? What
resources do you know of ?(psychiatrists, psychologists, counselors, etc.)
11) Do you travel to a different city for access to healthcare?
12) Assuming you have severe anxiety, where would you go to seek help? (Rank-Order
Question)
a. Psychiatrist
b. Psychologist
c. Therapist
d. Your primary care physician
e. Seek advice from friends/family
f. Online resources
13) Follow up to #12: If you only had access to a primary care physician and a
psychiatrist/psychologist was over an hour drive away, who would you choose to go to for your
first visit regarding mental health services?
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APPENDIX 4
Sample Decision Support Tool Dashboard
“Yellow Group”
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